文献速递产科

BMI≥40产妇剖宫产伤口缝合方式比较:缝线 vs 钉合

Cesarean wound closure in body mass index 40 or greater comparing suture to staples: a randomized clinical trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2020-10-27

该随机临床试验纳入BMI≥40的剖宫产产妇,比较皮内缝合与外科钉合对术后6周伤口并发症的影响。结果显示两组复合伤口并发症率无显著差异,但钉合组手术部位感染率显著更低。

要点

  • BMI≥40剖宫产产妇中,钉合与缝线的复合伤口并发症率无显著差异。
  • 钉合组手术部位感染率显著低于缝线组(10.5% vs 22.7%,P=.041)。
  • BMI、择期与否及研究站点是复合结局的独立预测因素。

核心结论

  • BMI≥40产妇剖宫产皮肤钉合或皮内缝合的复合伤口并发症率相似,但钉合组伤口感染率更低。

研究设计与样本

  • 随机临床试验,在2所大学医院将232名BMI≥40剖宫产产妇随机分至钉合组(n=117)或缝线组(n=115),按择期与否及站点分层。
  • 主要结局为产后6周内任何记录的伤口并发症,每组最终分析90人。

主要发现

  • 钉合组复合伤口并发症率为20.0%,缝线组为27.6%,差异无统计学意义(P≥.5)。
  • 钉合组手术部位感染率为10.5%,缝线组为22.7%,差异有统计学意义(P=.041)。
  • 多因素logistic回归显示BMI(OR=1.08,P=.004)、择期vs非择期剖宫产(OR=0.40,P=.018)和研究站点(OR=0.36,P=.028)是结局的独立预测因素。

关键数值与推荐

  • 样本量基于文献估算钉合组伤口并发症率20%、缝线组10%,power=0.80、双侧α=0.05,每组需199例。
  • 缝线组中三分之一使用编织缝线,三分之二使用单丝缝线;钉合组中位拆钉时间为术后5天。

临床怎么用

  • 对于BMI≥40的剖宫产产妇,可考虑使用外科钉合以降低手术部位感染风险,但需权衡复合伤口并发症无显著差异。

局限性

  • 因入组缓慢提前终止,实际分析每组仅90人,低于计划样本量。
  • 缝线组缝线类型由术者选择,存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cesarean delivery is the most common major surgical procedure performed in the United States. Women with class III obesity have an increased risk of cesarean delivery and have wound complication rates higher than healthy body mass index counterparts. Available evidence regarding optimal wound closure is lacking specific to the population of women with class III obesity despite a known increased rate of wound complications. OBJECTIVE: This study aimed to compare rates of postoperative wound complications among women with class III obesity (body mass index of ≥40 kg/m2) undergoing cesarean delivery with skin closure by either subcuticular suture or surgical staples. STUDY DESIGN: Patients were randomly assigned to skin closure by nonabsorbable stainless steel surgical staples or subcuticular suture of the surgeon's choice at the time of cesarean delivery at 2 university hospitals. Randomization was stratified for scheduled vs unscheduled cesarean delivery and for the 2 study sites. The primary outcome was the rate of any documented wound complication during the first 6 weeks after delivery. Any predictors of the composite outcome that in univariate analysis had a P<.20 were entered into a forward logistic regression. Sample size was calculated based on published literature and estimating the rate of wound complications within 6 weeks of follow-up at 20% with staples and 10% with sutures. For a power of 0.80 with a 2-tailed of 0.05, a total of 199 participants per group were required. RESULTS: From September 2015 to May 2019, 232 women were randomized to staples (n=117) or sutures (n=115). Nearing the planned interim analysis, enrollment in the study was concluded administratively owing to low enrollment. With loss to follow-up and exclusions, a total of 90 women were analyzed in each group. In the suture group, one-third was closed with braided suture and two-thirds were closed with monofilament suture. Median staple removal was 5 days postoperatively. Fewer composite wound complications were noted in the surgical staples group than the subcuticular suture group (20.0% vs 27.6%), although this difference was not statistically significant (P≥.5). The rate of surgical site infection was significantly lower in the staples group (10.5% vs 22.7%; P=.041). In the multiple logistic regression, the 3 significant independent predictors of the outcome were body mass index (odds ratio, 1.08; P=.004), scheduled vs unscheduled cesarean delivery (odds ratio, 0.40; P=.018), and study site (odds ratio, 0.36; P=.028). CONCLUSION: Surgical staples or subcuticular suture for skin closure at the time of cesarean delivery in women with a body mass index of ≥40 kg/m2 resulted in similar composite wound complication rates; however, lower cesarean wound infection rates were noted among wounds closed with staples.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Rodel RL, Gray KM, Quiner TE, et al. Cesarean wound closure in body mass index 40 or greater comparing suture to staples: a randomized clinical trial. Am J Obstet Gynecol MFM. 2020. PMID: 33451603. doi:10.1016/j.ajogmf.2020.100271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。